Marijuana stocks are varied and volatile. Choosing the right one can position lucky investors with a company that captures a significant portion of their niche market share. Medical and pharmaceutical companies have shifted their attention to cannabinoid-based medicines for the treatment of a variety of conditions. Much of the share price for cannabis biotechnology-related stocks is dependent on the timeline and results of their clinical trials.
As more medical cannabis drugs become approved and come to market, investors will be more willing to finance these marijuana biotech stocks primed for success. If you’re interested in investing in the promising cannabis biotech stock market, consider these top-performing stocks for your diverse portfolio.
Biotech Companies Bet on Synthetic Cannabinoids
Cannabinoids have been shown to be potent and effective treatment options for pain, inflammation, seizures, and other debilitating symptoms. Laboratory-created cannabinoids, however, are getting a spot in the limelight as biotech companies advance their clinical trials.
Drugs must gain FDA and DEA approval in order to come to the U.S. market. Because the plant can be hard to source and research, most of these biotech companies use lab-created cannabinoids with effective results.
GW Pharmaceuticals (Nasdaq:GWPH) may be the most popular and recognizable biotech pot stock on the market. Ever since its novel drug Epidiolex received FDA approval in June 2018 for severe forms of epilepsy, its product demand has exceeded expectations. Epidiolex was developed to treat Dravet syndrome and Lennox-Gaustat syndrome.
Apart from its innovative research on epileptic disorders, GW Pharmaceuticals is undergoing Phase 3 trials for tuberous sclerosis complex and multiple sclerosis spasticity. They’ve also begun studying CBDV for Rett syndrome and autism spectrum-related disorders. Expect GW to ramp up its European expansion relatively soon.
Botanix Pharma (ASX:BOT) is an up-and-coming biotech company in the dermatology field. According to their company website, their “mission is to improve the lives of patients suffering from serious skin diseases including acne, psoriasis, and atopic dermatitis using a novel therapeutic and advanced transdermal drug delivery system.” Botanix’ proprietary drug delivery systems utilize synthetic cannabidiol to treat the following:
- Moderate-to-severe acne
- Plaque psoriasis
- Atopic dermatitis
- Mild acne
The company recently announced a clinical program to treat rosacea and received tens of millions in funding to move their scheduled clinical trials forward. The company’s strong leadership and innovative thinking may bode well for an industry that hasn’t seen the likes of approved dermatological CBD treatments.
Zynerba Pharmaceuticals (Nasdaq: ZYNE) is currently studying the effects of synthetic CBD treatment for extremely rare disorders including Fragile X Syndrome (FSX), Autism Spectrum Disorder (ASD), 22q11.2 Deletion Syndrome (22q), and developmental and epileptic encephalopathies. Zynerba recently was awarded a patent for a synthetic CBD treatment for ASD, which can complement its current lead product, Zygel™, used for multiple rare disorders.
Cara Therapeutics (Nasdaq:CARA) is another clinical-stage biotech company looking to create historic treatment models. Cara’s focus is on “a novel class of peripherally acting kappa opioid agonist therapeutics with a primary focus for the treatment of pruritus.” Pruritus is associated with itchy skin and can develop along with chronic kidney disease, chronic liver disease, and atopic dermatitis. Cara Therapeutics is halfway through clinical trials for their proprietary formulations, which have, so far, proved to be significantly effective at reducing itch intensity.
MGC Pharmaceuticals (ASX:MXC),(MGCLF:OTC US) is a steadily rising European company with multiple phytomedicines including CannEpil for epilepsy and CogniCann for dementia and Alzheimer’s. Their “seed to pharma” approach focuses on research and development of various cannabinoid-based active pharmaceutical ingredients (API). MGC’s leadership has plenty of experience in the biotechnology industry and its euGMP-certified facilities have helped expand its operations throughout Europe, Australia, and now, Asia.
Impression Healthcare (ASX:IHL) has a strong foothold in Australia with operations based in Victoria, Australia. In addition, they’ve also secured a deal with Cannvalate, Australia’s largest distributor of cannabinoid-based medicines. Impression Healthcare made its mark as an oral device company to aid in sleep apnea, snoring, bruxism, and sports-related teeth injuries.
They’re currently undergoing clinical trials in collaboration with the Swinburne University of Technology to research CBD treatment of concussion, traumatic brain injuries, periodontitis, and temporomandibular joint disorder. In an effort to expand its commercial appeal and research real-world concussion treatment, Impression signed a deal with the MMA sports company, ONE Championship, in Asia.
Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals (Nasdaq:CRBP) has had some success in its clinical trials on its main product, lenabasum, for a wide range of conditions. Corbus bought the rights to the synthetic cannabinoid analog over a decade ago. Today, it’s moving forward with clinical studies for the treatment of inflammatory and fibrotic diseases. While some investors wait for more movement in the clinical trial phases, some investors aren’t waiting to bet large on this biotech stock.
Marijuana stock investors can consider biotech stocks in addition to more pure-play stocks relating to cannabis cultivation. Legalization across the world will provide cannabis biotech companies with even more opportunity to reduce symptoms in patients with common and rare disorders. Research is well under way for new cannabinoid-based medicines. As these biotech companies continue to see positive results, their stock worth will inevitably go up. Now’s the time for risk-taking investors to seriously consider biotech stocks.